# ğŸ¥ åŒ»è¯ç›‘ç®¡åŠ¨æ€æ—¥æŠ¥ (2026-02-11)

> ğŸ¤– è‡ªåŠ¨åŒ–æ•°æ®èŒƒå›´ï¼šæœ€è¿‘ 365 å¤© | ç›‘æ§èŠ‚ç‚¹ï¼šFDA, EMA, CDE, NMPA

## ğŸ›ï¸ FDA
- **[F.H. Investments Inc dba Asteria Health. Birmingham, AL. 483 issued 12/19/2025](http://www.fda.gov/about-fda/fda-commissioner/fh-investments-inc-dba-asteria-health-birmingham-al-483-issued-12192025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-02-10`
- **[Ipca Laboratories Limited - 12/5/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/ipca-laboratories-limited-1252025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-02-05`
- **[US Specialty Formulations LLC. Allentown, PA. 483 issued 1/14/2026](http://www.fda.gov/about-fda/fda-commissioner/us-specialty-formulations-llc-allentown-pa-483-issued-1142026)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-02-03`
- **[Baxter Oncology GmbH - 09/26/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/baxter-oncology-gmbh-09262025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-02-02`
- **[InnoStar Bio-Tech Nantong Company, Ltd - 11/1/2024](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/innostar-bio-tech-nantong-company-ltd-1112024)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-29`
- **[Empower Clinic Services LLC dba Empower Pharma. Houston, TX. 483 issued 12/14/2025](http://www.fda.gov/about-fda/fda-commissioner/empower-clinic-services-llc-dba-empower-pharma-houston-tx-483-issued-12142025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-27`
- **[Denver Solutions, LLC. Englewood, CO. 483 issued 12/11/2025](http://www.fda.gov/about-fda/fda-commissioner/denver-solutions-llc-englewood-co-483-issued-12112025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-26`
- **[Joinn Laboratories Co. Ltd. - 09/20/2013](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/joinn-laboratories-co-ltd-09202013)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-22`
- **[Nubratori, Inc. Torrance, CA. 483 issued 12/11/2025](http://www.fda.gov/about-fda/fda-commissioner/nubratori-inc-torrance-ca-483-issued-12112025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-22`
- **[Pine Pharmaceuticals LLC. Tonawanda, NY. 483 issued 11/14/2025](http://www.fda.gov/about-fda/fda-commissioner/pine-pharmaceuticals-llc-tonawanda-ny-483-issued-11142025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-22`
- **[Petscript Inc. Paris, TX. 483 issued 09/18/2025](http://www.fda.gov/about-fda/fda-commissioner/petscript-inc-paris-tx-483-issued-09182025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-22`
- **[Asahi Kasei Finechem Co., Ltd. - 11/14/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/asahi-kasei-finechem-co-ltd-11142025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-22`
- **[Sato Pharmaceutical Co., Ltd. - 11/21/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/sato-pharmaceutical-co-ltd-11212025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-21`
- **[Lupin Limited - 09/16/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/lupin-limited-09162025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-21`
- **[JKR Pharmacy Ventures, LLC dba Doc Laneâ€™s Veterinary Pharmacy. Lexington, KY. 483 issued 12/19/2025](http://www.fda.gov/about-fda/fda-commissioner/jkr-pharmacy-ventures-llc-dba-doc-lanes-veterinary-pharmacy-lexington-ky-483-issued-12192025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-20`
- **[Fresenius Kabi Compounding LLC. Canton, MA. 483 issued 11/05/2025](http://www.fda.gov/about-fda/fda-commissioner/fresenius-kabi-compounding-llc-canton-ma-483-issued-11052025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-20`
- **[McNeil Healthcare, LLC, Las Piedras, PR 483 issued 11/02/2010](http://www.fda.gov/about-fda/mcneil-healthcare-llc-las-piedras-pr-483-issued-11022010)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-16`
- **[Inotiv Inc. - 10/24/2025](http://www.fda.gov/drugs/cder-foia-electronic-reading-room/inotiv-inc-10242025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-16`
- **[OSRX Inc. Missoula, MT. 483 issued 11/14/2025](http://www.fda.gov/about-fda/fda-commissioner/osrx-inc-missoula-mt-483-issued-11142025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-16`
- **[Qualgen LLC. Edmond, OK. 483 issued 09/04/2025](http://www.fda.gov/about-fda/fda-commissioner/qualgen-llc-edmond-ok-483-issued-09042025)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-16`

## ğŸ›ï¸ EMA
- **[Concept paper on the revision of the guidelines on Good Manufacturing Practice for medicinal products - Annex 15 - Qualification and validation](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guidelines-good-manufacturing-practice-medicinal-products-annex-15-qualification-validation_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-02-09`
- **[Concept paper for the development of a reflection paper on the use of Bayesian methods in clinical development](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-reflection-paper-use-bayesian-methods-clinical-development_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-30`
- **[Concept paper on the revision of the guideline on clinical evaluation of diagnostic agents and its appendix 1 on imaging agents](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-revision-guideline-clinical-evaluation-diagnostic-agents-its-appendix-1-imaging-agents_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-30`
- **[Concept paper on the development of a guideline for using owner assessment as efficacy parameter](https://www.ema.europa.eu/en/documents/scientific-guideline/concept-paper-development-guideline-using-owner-assessment-efficacy-parameter_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-23`
- **[Draft guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees - Revision 2](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-veterinary-medicinal-products-controlling-varroa-destructor-parasitosis-bees-revision-2_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-23`
- **[Draft guideline for the evaluation of efficacy of ectoparasiticides - general requirements](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-efficacy-ectoparasiticides-general-requirements_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-23`
- **[Draft guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs) - Revision 1](https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-requirements-combined-vaccines-associations-immunological-veterinary-medicinal-products-ivmps-revision-1_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-23`
- **[Reflection paper on investigation and assessment of cardiovascular safety of anticancer medicinal products](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-investigation-assessment-cardiovascular-safety-anticancer-medicinal-products_en.pdf)**
  - ğŸ—“ï¸ å‘å¸ƒæ—¥æœŸ: `2026-01-23`

